| |
Thursday, July 10, 2025 | 10am ET / 7am PT The transition from drug discovery to process development poses significant challenges. Join us for this deep dive into how adopting a collaborative approach between medicinal and process chemistry teams can help address key obstacles and accelerate progress from discovery to early clinical milestones. Register now. 
|
|
Today’s Big NewsJun 24, 2025 |
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now. 
|
|
| By Gabrielle Masson Sangamo Therapeutics’ investigational gene therapy appears to improve kidney function at 52 weeks for patients with a rare genetic disorder. |
|
|
|
By Angus Liu Sen. Bill Cassidy, M.D., R-La., has come out critical of Robert F. Kennedy Jr.’s picks for the CDC’s vaccine advisory panel, calling for the committee’s upcoming meeting to be postponed. |
By Conor Hale The former Fierce 15 winner’s Oryom robot aims to start with a clinical trial in cataract procedures, though it is designed to reach any point within the eye. |
By Zoey Becker The company noted high rates of discontinuation due to gastrointestinal events, such as vomiting, in fixed-dose arms of its phase 2 trial. |
|
The biologics development and manufacturing sector has long been at the forefront of innovation, consistently driving therapeutic advancements for a wide array of complex diseases. While demand has never been greater, there are still many technical challenges. This valuable resource uncovers how to navigate today’s top obstacles. Download now. 
|
|
By Kevin Dunleavy The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer. |
By James Waldron Rivus’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the drug's obesity potential. |
By James Waldron Revolution Medicines has secured a potential funding infusion of up to $2 billion from Royalty Pharma in return for a slice of the profits if Revolution’s lead cancer drug makes it to market. |
By Kevin Dunleavy Amarin has forged a licensing deal with Italian pharma Recordati to commercialize its fish oil-derived heart pill Vascepa. Recordati will pay Amarin $25 million upfront to market the product to 59 European countries. |
By Nick Paul Taylor Publicis Health has snapped up another Omnicom Health Group executive. Six months after Matt McNally took up the global CEO post at Publicis, Craig Romanok has landed the chief commercial officer position at the agency’s Digitas Health unit. |
By Conor Hale The Paris-based company’s atraumatic method for repairing nerves in the arms, hands and legs employs a light-activated biopolymer platform, first invented by researchers at MIT and Brigham & Women’s Hospital. |
By Andrea Park The Bloc is building out its European presence, as the New York-based independent health agency announced Tuesday the formation of its first London outpost. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates. |
|
|---|
|
|
|
QPS leverages a combination of clinical and regulatory expertise, exceptional data scientists, and AI to deliver RWE studies that support accelerated drug development for biotech clients. Learn More. +(2)+(2)+(1).png)
|
|
Whitepaper We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| Deadline Extended: July 2 |
|
| Sheraton Philadelphia Downtown |
|
|
| |
|
